DYRK1A and Down syndrome: Among the natural inhibitors for DYRK1A, green tea-derived epigallocatechin-3-gallate (EGCG) shows potent selective inhibition in both Down syndrome-related symptoms and tumourigenesis [5, 6], further clinical trials on EGCG would offer more empirical evidence and improve the understanding of its functional activity in cancer development [NCT02891538 (colorectal cancer), NCT02577393 (lung cancer) etc.]